Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas - Drug Trials For Money - Paid Clinical Trials

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Conditions:   Epstein-Barr Virus Associated Lymphoproliferative Disorder;   EBV-Related PTLD;   EBV Related Non-Hodgkin’s Lymphoma;   Extranodal NK/T-cell Lymphoma;   EBV-Positive DLBCL, Nos;   EBV Associated Lymphoma;   EBV-Related Hodgkin Lymphoma;   EBV Related PTCL, Nos
Intervention:   Drug: Nanatinostat in combination with valganciclovir
Sponsor:   Viracta Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 19, 2021 / by / in
Comments